



## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India  
Tel: +91-8532-238704, Fax: +91-8532-238876  
Email: info@vbszilpa.com, Web: www.vbszilpa.com  
CIN: L85110KA1987PLC008739

Date:23-07-2024

To,

Corporate Relationship Department,  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
**Mumbai-400 001**

National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No.C/1, G Block  
Bandra Kurla Complex, Bandra (E)  
**Mumbai-400 051**

Dear Sir/Madam,

**Sub:** Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.  
**Ref:** Stock Code: NSE: SHILPAMED/BSE-530549

**Important milestone for the biologics business of Shilpa Medicare Limited ("SML")  
Shilpa Biologics Pvt Ltd ("SBPL") receives first international market approval for Adalimumab 40 mg/  
0.4 mL Solution for Injection in MOROCCO**

This is to inform you that Shilpa Biologicals Pvt Ltd (SBPL), a wholly owned subsidiary of the Company has received registration approval for Adalimumab from Morocco, MoH . This is **the first Biosimilar approval from any international market for high concentration Adalimumab developed by SBPL.**

#### **Brief information about product:**

- Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL). Adalimumab contains Adalimumab as an active ingredient. Adalimumab is a fully human monoclonal IgG1 antibody produced recombinantly by Chinese Hamster Ovary (CHO) cells. Adalimumab consists of 1330 amino acid containing glycoprotein which has two copies of heavy- and two copies of light-chains in heterodimeric form with a molecular weight of 148 kDa (approx.). Adalimumab binds specifically to Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) and blocks its interaction with the p55 and p75 cell surface TNF receptor. Adalimumab is indicated for Rheumatoid Arthritis (RA) in adults.
- The Adalimumab 40 mg/ 0.4 mL Solution for Injection is highly similar to the innovator (Humira) with respect to Quality, Safety and Efficacy.

SBPL has aggressively submitted its Adalimumab dossier in more than 15 emerging markets countries and is in the process of submitting the dossier to other countries as well.

#### **About Shilpa:**



## ***Shilpa Medicare Limited***

### **Corporate & Admin Office:**

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,  
Raichur – 584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: [info@vbshilpa.com](mailto:info@vbshilpa.com), Web: [www.vbshilpa.com](http://www.vbshilpa.com)

CIN: L85110KA1987PLC008739

Shilpa is an integrated pharmaceutical group with business interests in niche Oncology & Non-oncology APIs, Peptides, Polymers, differentiated finished dosage formulations including orally dispersible films & transdermal patches along with carefully crafted biological portfolio. Shilpa also provides end-to-end CDMO services to global pharmaceutical companies across all its business segments based on its strong R&D and manufacturing capabilities backed by four R&D units and seven manufacturing facilities.

### **About Shilpa Biologicals Pvt Ltd:**

Shilpa Biologicals is a fully integrated biopharmaceutical company with therapeutic focus on immunology and ophthalmics. The company's disruptive technology platforms enable patient access to high quality, cutting edge biopharmaceuticals in the global markets. The company currently has a pipeline of biosimilars at various stages of development including one commercialised product in the Indian market. The company is also now catering to the growing demand from its global customers for high quality developmental and manufacturing work from its facility in Dharwad, Karnataka.

**With Regards,  
For SHILPA MEDICARE LIMITED**

Ritu Tiwary  
Company Secretary & Compliance Officer